Company News

pages-1x1

Revolutionizing Drug Development: Synthetic Nanodiscs

December 6, 2023 Time: 7:00 AM CST

Unlock the Potential of ‘Undruggable’ Membrane Proteins

pages-Cancer 2023 1080x1080 1

Cancer Research & Immuno-Oncology Week Virtual Event Series 2023

Activity time: October 3 – 5, 2023

DIMA invites you to attend the Cancer Research & Immuno-Oncology Week Virtual Event Series, an online-only virtual event occurring on October 3 – 5, 2023.

DIMABIO Summer Price-small icon

Summer Promotion-Popular drug target proteins with 50% OFF

Activity time: 2023.07.01-2023.09.01

In order to appreciate customers’ attention on DIMABIO, we offer 50% OFF on selective Extracellular Domain (ECD) protein products.

PEGS Boston: The Essential Protein Engineering & Cell Therapy Summit 2023

Dates: May 15th -19th, 2023
Location: Boston, MA – Hynes Convention Center and virtual 

Using Single B Technology to Develop Lead Antibody Molecules on GPCR Targets with Live Q&A

2023-02-09

We’re presenting at the Drug Discovery ……

Immuno-Oncology target|BCMA (1)

2020-09-30

The racetrack is crowded……

Will SIRPα antibody combinatorial therapy be the next research hotspot?

2020-09-02

SIRPα, a transmembrane protein expressed on macrophages and bone marrow cells, binds to its ligand CD47 to produce a “don’t eat me” signal that prevents macrophages from phagocytizing healthy cells.

Immune checkpoints proteins

2020-07-29

Immune checkpoints are regulators that can inhibit or activate our immune system. They play essential roles in maintaining immune tolerance and modulating the duration and strength of immune responses.

New product release: SARS-CoV-2 functional proteins

2020-07-15

To help our customers quickly evaluta the bioactivity of our SARS-CoV-2 S protein products, we include two small packages of CB6 and CR3022 monoclonal antibodies as free sample kit if you order the standard 100 ug or above package.

Events of 2020

2020-04-26

Dima Biotech is attending or presents new products in the following international conferences:

First full length rabbit sourced mAb approved by FDA

2020-03-14

FDA approved the listing of Eptinezumab, a CGRP antibody of Danish Lundbeck pharmaceutical, under the trade name of Vyepti, to prevent migraine On February 22, 2022. Since 1986, FDA has approved more than 90 new monoclonal antibody…